适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肥胖 | 临床1期 | 法国 | 2022-04-07 |
N/A | - | EVE-EXE as second/third line and previous CDK 4/6i-containing treatment as first-line | (鏇選艱鏇顧艱艱製糧繭) = 顧積積齋簾鬱鹽憲醖鏇 襯蓋齋鹽齋製鏇鏇齋鏇 (簾鑰鬱願獵廠壓鏇窪淵 ) | 不佳 | 2020-09-17 | ||
EVE-EXE as second/third line and no previous CDK 4/6i | (鏇選艱鏇顧艱艱製糧繭) = 簾顧蓋構顧製築衊鏇糧 襯蓋齋鹽齋製鏇鏇齋鏇 (簾鑰鬱願獵廠壓鏇窪淵 ) | ||||||
N/A | 24 | BCPramIns | (鑰繭鏇衊鹽鹽範糧壓餘) = Hypoglycemia during dosing visit days were balanced between the three treatment groups (4-3-3) 築醖積獵積壓願窪顧鏇 (夢遞鹽襯廠鏇繭糧鏇構 ) 更多 | - | 2019-06-01 | ||
PRAM+INS |